Survivor

Lost to follow up

Dead

Nine months of treatment since the development of resistance

DOC-P (n = 59)

32 (54.24%)

16 (27.12%)

11 (18.64%)

Weekly-Taxol (n = 6)

2 (33.33%)

1 (16.67%)

3 (50%)

Ac Abir (n = 8)

3 (37.50%)

1 (12.50%)

4 (50%)

Purely symptomatic approach. (n = 11)

2 (18.18%)

2 (18.18%)

7 (63.64%)